MedPath

Mallinckrodt Pharmaceuticals

🇨🇦Canada
Ownership
-
Established
2013-01-01
Employees
-
Market Cap
$4.5M
Website
http://www.mallinckrodt.com/

Yaqrit Advances L-ornithine Phenylacetate to Phase 3 for Acute Hepatic Encephalopathy Treatment

Yaqrit's subsidiary Amalive is preparing to launch Phase 3 trials in 2025 for L-ornithine phenylacetate (OPA), an ammonia scavenger acquired from Mallinckrodt Pharmaceuticals, targeting acute hepatic encephalopathy.

© Copyright 2025. All Rights Reserved by MedPath